CareRx Corporation

For Q2 2026, CareRx reported revenue of $93.6 million, up from $91.4 million in Q2 2025; adjusted EBITDA was $8 million, essentially flat year over year, and adjusted EBITDA margin was 8.6% versus 8.8% last year. Net income was approximately $400,000, down from $600,000 in the prior-year quarter, and cash from operations was $3.7 million versus $3.8 million a year ago. Average beds serviced rose to 91,719 from 90,048. Management said the Ontario ward-bed funding change created about a $667,000 impact in Q2 and reiterated a full-year top-line impact of about $2 million. Looking ahead, the company expects the newly won 3,000 retirement beds to be fully onboarded during Q3, with the full EBITDA benefit showing up in Q4; the board also approved a dividend increase to $0.022 per share, payable October 8, 2026.

Puneet Khanna characterized the quarter as consistent and said the business is benefiting from prior-year bed adds, cost savings, and operational efficiency initiatives. He highlighted the 3,000-bed win as a milestone that validates CareRx’s service quality, clinical expertise, resident safety, and technology offerings. He also emphasized disciplined capital allocation, including the dividend increase, and said the company remains bullish on the pipeline and focused on organic bed growth.

Suzanne Brand said Q2 revenue of $93.6 million and adjusted EBITDA of $8 million were consistent with the prior year, while margin slipped modestly to 8.6% from 8.8% because of Ontario ward-bed funding changes. She noted cash of $9.6 million at June 30, 2026, down from $14.8 million at the end of Q1 due to capital expenditures and debt repayment, and net debt of $29.1 million versus $25 million in Q1, or 0.9x net debt to adjusted EBITDA. She reiterated that the board approved the $0.022 dividend and said the balance sheet remains strong and conservative.

Analysts focused on the Ontario ward-bed funding change, the timing and economics of the new 3,000-bed contract, and whether additional bed growth is still on track. Management said the ward-bed revenue headwind remains about $2 million for the full year, with about $667,000 felt in Q2, and that the lost funding should eventually come back once the ward beds are redeveloped, likely not until late 2027. On the 3,000 beds, management said onboarding started in Q3 and will be complete before quarter-end, with no surprise in the margin contribution and full impact expected in Q4. They also said the new customer is a full-portfolio win, with no incremental beds to add later, and that the company is roughly halfway to the low end of its 6,000-8,000 organic bed-add target.